The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection

被引：2

作者：

Ozdener, Ayse Elif ^{[1
]}

Park, Tae Eun ^{[2
,3
]}

Kalabalik, Julie ^{[1
]}

Gupta, Rachna ^{[4
]}

机构：

[1] Fairleigh Dickinson Univ, Sch Pharm & Hlth Sci, Florham Pk, NJ 07932 USA

[2] Touro Coll Pharm, New York, NY USA

[3] Suny Downstate Med Ctr, Dept Pharm, Brooklyn, NY 11203 USA

[4] Infect Dis Care, Randolph, NJ USA

来源：

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2017年 / 15卷 / 05期

关键词：

Pre-exposure prophylaxis; PrEP; HIV; human immunodeficiency virus; antiretroviral; LONG-ACTING RILPIVIRINE; TENOFOVIR DISOPROXIL FUMARATE; COST-EFFECTIVENESS; ANTIRETROVIRAL PROPHYLAXIS; PROTECTS MACAQUES; RHESUS MACAQUES; ORAL MARAVIROC; AFRICAN WOMEN; UNITED-STATES; VAGINAL RINGS;

D O I：

10.1080/14787210.2017.1309292

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Introduction: People at high risk for HIV acquisition should be offered pre-exposure prophylaxis (PrEP). Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) is currently the only medication recommended for pre-exposure prophylaxis (PrEP) by the Centers for Disease Control and Prevention (CDC) in people at high risk for HIV acquisition. This article will review medications currently under investigation and the future landscape of PrEP therapy.Areas covered: This article will review clinical trials that have investigated nontraditional regimens of TDF/FTC, antiretroviral agents from different drug classes such as integrase strand transfer inhibitors (INSTI), nucleoside reverse transcriptase inhibitors (NRTI), and non-nucleoside reverse transcriptase inhibitors (NNRTI) as potential PrEP therapies.Expert commentary: Currently, there are several investigational drugs in the pipeline for PrEP against HIV infection. Increased utilization of PrEP therapy depends on provider identification of people at high risk for HIV transmission. Advances in PrEP development will expand options and access for people and reduce the risk of HIV acquisition.

引用

页码：467 / 481

页数：15

共 75 条

[1]

Abdool KarimQ., 2010, Science, V329, P1168, DOI DOI 10.1126/SCIENCE.1193748

[2]

[Albert Einstein College of Medicine Inc . ClinicalTrials.gov], 2000, SAF PHARM PK POL TEN

[3] Study Product Adherence Measurement in the iPrEx Placebo-Controlled Trial: Concordance With Drug Detection [J].

Amico, K. Rivet ;

Marcus, Julia L. ;

McMahan, Vanessa ;

Liu, Albert ;

Koester, Kimberly A. ;

Goicochea, Pedro ;

Anderson, Peter L. ;

Glidden, David ;

Guanira, Juan ;

Grant, Robert .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 66 (05) :530-537

[4] A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge [J].

Andrews, Chasity D. ;

Yueh, Yun Lan ;

Spreen, William R. ;

St Bernard, Leslie ;

Boente-Carrera, Mar ;

Rodriguez, Kristina ;

Gettie, Agegnehu ;

Russell-Lodrigue, Kasi ;

Blanchard, James ;

Ford, Susan ;

Mohri, Hiroshi ;

Cheng-Mayer, Cecilia ;

Hong, Zhi ;

Ho, David D. ;

Markowitz, Martin .

SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (270)

[5] Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus [J].

Andrews, Chasity D. ;

Spreen, William R. ;

Mohri, Hiroshi ;

Moss, Lee ;

Ford, Susan ;

Gettie, Agegnehu ;

Russell-Lodrigue, Kasi ;

Bohm, Rudolf P. ;

Cheng-Mayer, Cecilia ;

Hong, Zhi ;

Markowitz, Martin ;

Ho, David D. .

SCIENCE, 2014, 343 (6175) :1151-1154

[6]

[Anonymous], 2014, PREEXP PROPH PREV HI

[7]

[Auritec pharmaceuticals ClinicalTrials. gov], 2000, SAF PHARM STUD HIV P

[8] Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women [J].

Baeten, J. M. ;

Palanee-Phillips, T. ;

Brown, E. R. ;

Schwartz, K. ;

Soto-Torres, L. E. ;

Govender, V. ;

Mgodi, N. M. ;

Kiweewa, F. Matovu ;

Nair, G. ;

Mhlanga, F. ;

Siva, S. ;

Bekker, L. -G. ;

Jeenarain, N. ;

Gaffoor, Z. ;

Martinson, F. ;

Makanani, B. ;

Pather, A. ;

Naidoo, L. ;

Husnik, M. ;

Richardson, B. A. ;

Parikh, U. M. ;

Mellors, J. W. ;

Marzinke, M. A. ;

Hendrix, C. W. ;

van der Straten, A. ;

Ramjee, G. ;

Chirenje, Z. M. ;

Nakabiito, C. ;

Taha, T. E. ;

Jones, J. ;

Mayo, A. ;

Scheckter, R. ;

Berthiaume, J. ;

Livant, E. ;

Jacobson, C. ;

Ndase, P. ;

White, R. ;

Patterson, K. ;

Germuga, D. ;

Galaska, B. ;

Bunge, K. ;

Singh, D. ;

Szydlo, D. W. ;

Montgomery, E. T. ;

Mensch, B. S. ;

Torjesen, K. ;

Grossman, C. I. ;

Chakhtoura, N. ;

Nel, A. ;

Rosenberg, Z. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (22) :2121-2132

[9] Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women [J].

Baeten, J. M. ;

Donnell, D. ;

Ndase, P. ;

Mugo, N. R. ;

Campbell, J. D. ;

Wangisi, J. ;

Tappero, J. W. ;

Bukusi, E. A. ;

Cohen, C. R. ;

Katabira, E. ;

Ronald, A. ;

Tumwesigye, E. ;

Were, E. ;

Fife, K. H. ;

Kiarie, J. ;

Farquhar, C. ;

John-Stewart, G. ;

Kakia, A. ;

Odoyo, J. ;

Mucunguzi, A. ;

Nakku-Joloba, E. ;

Twesigye, R. ;

Ngure, K. ;

Apaka, C. ;

Tamooh, H. ;

Gabona, F. ;

Mujugira, A. ;

Panteleeff, D. ;

Thomas, K. K. ;

Kidoguchi, L. ;

Krows, M. ;

Revall, J. ;

Morrison, S. ;

Haugen, H. ;

Emmanuel-Ogier, M. ;

Ondrejcek, L. ;

Coombs, R. W. ;

Frenkel, L. ;

Hendrix, C. ;

Bumpus, N. N. ;

Bangsberg, D. ;

Haberer, J. E. ;

Stevens, W. S. ;

Lingappa, J. R. ;

Celum, C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (05) :399-410

[10]

Bekker L-G, 2015, HPTN 067 ADAPT BACKG

← 1 2 3 4 5 6 7 8 →